Physician profile
Christopher Ginocchio
NPI 1346274131
$1,963.04
in general payments reported to CMS, 2019-2025
27 companies · $87.31 in 2025
The $87.31 reported for 2025 was less than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,447 · 2020: $297 · 2021: $16.74 · 2023: $95.87 · 2024: $18.59 · 2025: $87.31.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $202.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $201.77 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $269.83 | 2019-2020 | |
| Sunovion Pharmaceuticals INC. | $235.39 | 2019-2020 | |
| Supernus Pharmaceuticals, INC. | $222.47 | 2019-2020 | |
| Emd Serono, INC. | $201.72 | 2019-2020 | |
| Ucb, INC. | $191.02 | 2019-2020 | |
| Argenx US, INC. | $95.87 | 2023 | Vyvgart |
| Livanova USA, INC. | $94.76 | 2019-2020 | |
| Acadia Pharmaceuticals INC | $79.29 | 2019 | |
| Allergan, INC. | $74.78 | 2019 | |
| Novartis Pharmaceuticals Corporation | $72.86 | 2019 | |
| Biogen, INC. | $66.07 | 2019-2020 | |
| Sk Life Science, INC. | $60.22 | 2025 | |
| Csl Behring | $44.86 | 2019-2020 | |
| Acorda Therapeutics, INC | $30.96 | 2019 | |
| Abbvie INC. | $27.09 | 2025 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Upsher-Smith Laboratories LLC | $26.04 | 2019 | |
| Amgen INC. | $20.45 | 2019 | |
| Lundbeck LLC | $19.38 | 2020 | |
| Neuropace, INC. | $18.59 | 2024 | |
| Alexion Pharmaceuticals, INC. | $17.40 | 2019 | |
| Celgene Corporation | $16.74 | 2021 | |
| Adamas Pharmaceuticals, INC. | $14.50 | 2019 | |
| Neurocrine Biosciences, INC. | $13.51 | 2020 | |
| Medtronic Vascular, INC. | $13.21 | 2019 | |
| Travere Therapeutics, INC. | $12.45 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $12.37 | 2020 | |
| Sanofi-Aventis U.S. LLC | $11.21 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christopher Ginocchio listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.